Antagonistic analogues of luteinizing hormone-releasing hormone (LHRH) belong to a class of compounds that can be utilized for treatment of some hormonedependent cancers and gynecologic disorders. Recently, we synthesized and tested a large number of LHRH analogues for LHRH antagonistic activity in the dispersed pituitary cell superfusion system. This fast, reliable, and dynamic system made it possible for us not only to evaluate the relative amounts of an analogue required for suppression of the LH-releasing activity of exogenous LEIRH but also provided quantitative data on dynamic interactions between the LHRH analogue, LHRH receptors, and LH secretion. Three experimental paradigms were used: (i) LHRH responses after preincubation with the antagonist, (ii) pulsatile, simultaneous infusion of LHRH and the antagonistic analogue, and (iW) effects of the analogues on ongoing, continuous LH secretion induced by prolonged stimulation with LHRH. From the data obtained, we conclude that (') the suppression of the LHRH-induced LH release was more effective and longer lasting when the cells were preincubated with the antagonistic analogues before the LBRH stimulation than in the case of simultaneous exposure; (ui) not only the potency but also the time of onset and the duration of the LH release-suppressing activity varied according to the different peptides used, resulting in different shapes of response curves; and (ii) from the accurate data obtained in this dynamic system, quantitative parameters of the in vivo interactions between the antagonists and LBRH on the LHRH receptor can be calculated.
In the past few years, a large number of antagonists of luteinizing hormone-releasing hormone (LHRH) has been synthesized and evaluated for therapeutic use (1) (2) (3) (4) (5) (6) . These analogues may have various practical applications, including treatment of gynecologic disorders and hormone-sensitive tumors such as prostate and breast cancers (1, 2, (7) (8) (9) . Although chronic administration of LHRH agonists is necessary for inhibition of LH, a single dose of a potent LHRH antagonist is sufficient to evoke the same effect (1, 2, 5-13). Agonists, unlike antagonists, induce a LH surge before the LH secretion blockade takes effect, which may result in an undesirable flare-up (1, 2) . The bioactivity of a newly synthesized peptide must be tested by the most efficacious means. Although the final evaluation always has to be made in vivo, for screening purposes the simpler, less expensive, faster, and more accurate in vitro bioassays are the methods of choice. In vitro assays are especially suitable to test hypothalamic hormones since (i) their target organ, the pituitary, can be obtained easily; (ii) the pituitary cells survive and function well in an artificial environment; and (iii) RIA methods are widely available to measure the response, based on the pituitary hormone release.
In vitro pituitary bioassays were described as early as 1955 (14) . Although this static system provided valuable help in isolation and characterization of several hypothalamic hormones (15) , this method is unsatisfactory for providing data on the dynamics of hormone release. The static system may also be less informative when more complex approaches, such as determining the bioactivity of antagonistic analogues, are used. During the several hours of incubation, the released hormones and other metabolic products accumulate in the medium and may affect the metabolism of the cells and reduce further hormone secretion. Proteolytic enzymes, present in the incubation medium, may also digest the test material and the secreted hormone.
Systems in which tissue culture medium is perfused continuously through surviving tissues are devoid of these drawbacks. Thus, it is possible to add the test material in a more physiological, pulsatile way (16) . The sampling can also be more refined and, consequently, the dynamics, the timing, and subtle changes in the responsiveness can also be analyzed. Although the terminology has not been standardized, the method is generally called "perifusion" when whole organs or organ segments are used and "superfusion" when dispersed cells are utilized (16) .
Recently we designed, synthesized, and tested >100 antagonistic LHRH analogues (1, 2, 5, 6, 11) . Some of them proved to be highly potent and free from edematogenic effects. The LHRH antagonists were also very effective in suppressing the growth of experimental mammary cancers and prostate tumors (7, 9) . To assess the bioactivity of these compounds, the dispersed rat pituitary superfusion system was initially used (5, 6) . Utilizing this dynamic method, various experimental techniques were used in search of the most informative approach. In the course of our work, we also wanted to obtain data on the reliability of this in vitro system in testing antagonistic analogues of LHRH and acquire a deeper insight into the physiology of pituitary hormone secretion. This paper summarizes and analyses our experiences with the in vitro superfusion system related to control of LH secretion from pituitary cells.
MATERIALS AND METHODS
Superfusion. Dispersed rat pituitary cell superfusion was performed as described (16 collagenase (no. CLS-II; Worthington) for 1 hr followed by a mechanical dispersion. The resulting cell suspension from 1.5 pituitaries, containing mostly small clusters of cells, was then sedimented together with a suspension of Sephadex G-10 (Sigma) and packed into 6.6-mm columns. The dead volume of the system was carefully set to 1 ml. Tissue culture medium 199 (Sigma) with supplements (16), equilibrated with 95% air/5% carbon dioxide, was perfused through the columns at a flow rate of 0.33 ml/min. After an overnight recovery period, during which the baseline stabilized and the cells regained their full responsiveness (16) , the samples to be tested were introduced through a four-way valve. During the 8.5-to 9-hr experimental period, 170-180 one-ml fractions were collected. The system was standardized with 3-min exposures to 100 mM potassium chloride (16) were designed, synthesized, and purified in our laboratory as described (5, 6) . [Nal(2), 3-(2-naphthyl)alanine; Pal(3), 3-(3-pyridyl)alanine; Cit, citrulline; Hci, homocitrulline; Phe(4C1), 4-chlorophenylalanine; Moc, methyloxycarbonyl.] RESULTS LH Response to LHRH Stimulation. Stimulation of the dispersed rat pituitary cells for 3 min with 3 nM LHRH resulted in a sharp, transient increase in LH secretion. The onset of the LH release was very rapid: the leading edge of the response peak followed -the beginning of the stimulus within 20 sec, as revealed by data from experiments with a shorter fraction time. The LH release also stopped rapidly.
The elevated LH level returned to the baseline with 6.66 ± 0.42 min half-time (T50). Cells of one pituitary secreted 26 ± 2.15 ng of LH during a response (NET TNT value). When the stimulation was repeated at 30-min intervals for 8 hr, distinct peaks of similar size and shape were obtained (Fig. 1) Although the basal LH secretion of the cells (0.55 ± 0.08 ng/ml) was well above the sensitivity limit of the RIA (0.12 ng/ml), no significant decrease in LH secretion was detected, provided sufficient time had elapsed after a nonspecific or specific stimulation to obtain the "real" basal secretion (Fig. 3, with LHRH (Fig. 3 , responses C-E). In cases in which a detectable decrease in the "basal" LH secretion was experienced following administration of an analogue, the cells proved to be in a slightly stimulated condition because of (i) too short a time had elapsed after a test stimulation, (ii) the recovery period after the column preparation (mechanical stimulation) was too short (<5 hr), or (iii) the cells had not recovered from a temporary mechanical or chemical stress due to malfunctions of the system (vibration of the column, air bubble entering or forming in the column, or the pressure of the medium had changed as a consequence of a partial block of the medium flow).
LH Response After Preincubation with Antagonists. In these experiments, the cells were exposed to a 3 nM solution of the antagonists for 9 min and then to a mixture of 3 nM concentration of the same antagonist and 3 nM LHRH for an additional 3 min (Fig. 3, response G) . To test changes in LH responsiveness of the cells, 3 nM LHRH was also given for 3 min at 30-min intervals, three or four times thereafter (Fig.  3, responses H-K) .
LH response to LHRH was markedly reduced after exposure of the cells to the antagonist, followed by a gradual recovery period. Using this experimental protocol, different patterns in the alterations ofthe LH responsiveness to LHRH were found following the exposure to antagonistic LHRH analogues, depending on their chemical structure. we obtained. These were (i) fast appearance followed by a rapid disappearance of the inhibition of LH release (SB-92), (ii) fast onset of the release blockade with a long-lasting inhibitory effect (SB-75), (iii) gradual increasing effect even after a single, short exposure (SB-29), and (iv) significant augmentation of the LH release, following a brief inhibitory period (SB-102). Some ofour antagonists (e.g., SB-75, SB-29) proved to be very potent, for instance, following a single exposure at 3 nM concentration, and the normal LH responsiveness was not reestablished even by the end of the 8-hr experiment, rendering the system unfit for further analysis.
Regression analysis was performed on the relative inhibitory effect of the analogues (% of the NET INT values of the response curve) plotted against time. From these data, the time required for complete recovery of the LH responsiveness can be calculated. Based on these calculations the recovery times for SB-92, SB-75, SB-29, and SB-102 were 3.8 hr, 35.8 hr, 46.5 hr, and 10.9 min, respectively.
Testing of LHRH Antagonist with Simultaneous Administration of LHRH and the Antagonist. A mixture of 30 nM antagonist and 3 nM LHRH was applied for 3 min (Fig. 3 , response M), followed by four consecutive LHRH exposures (3 nM for 3 min) at 30-min intervals (Fig. 3, responses N-Q) . Although the concentration of the peptides was 10 times higher than that in the previous series of experiments, the inhibition of the LH release was greatly diminished, both in intensity and duration (compare Fig. 3 , responses G-K with M-Q).
Effects of Antagonists on Ongoing LHRH-Induced LH Release. In this series of experiments, the cells were exposed to 1 nM LHRH continuously for 150 min. Thirty minutes after the start of LHRH stimulation, 30 nM antagonist SB-75 was also infused for 3 min (Fig. 2, response F) . The analogue caused an immediate reduction (within 1 min) in LH secretion, which showed a tendency for a recovery, but did not reach control levels before the end of the LHRH infusion.
Interaction Between the Antagonist Analogue and the Potassium Response. Temporary increase in K+ concentration in the medium is a frequently used, nonspecific, but reproducible way of stimulating of the peptide secretion. In our system, 100 mM increase in K+ concentration for 3 min results in a rapid, brief LH response, similar in area (NET INT value) to that obtained after 3 nM LHRH stimulation (16) (Fig. 5, responses A, B , and E).
To check if the potassium response is modified by the antagonist, previous experiments were repeated by substi- 5 . LH responses to temporary elevation of potassium concentration in dispersed rat pituitary superfusion. Potassium concentration of the medium was elevated by 100 mM for 3 min (A, B, E, and F). The increase in LH secretion is transitory and the subsequent responses to LHRH (3 nM for 3 min) (C and D) are not altered. A 9-min preincubation with 3 nM SB-75 followed by simultaneous exposure to 3 nM SB-75 with 100 mM potassium chloride did not decrease the response to potassium significantly (F). However, an effective blockade of the release mechanism is indicated by the diminished LH responsiveness to consecutive LHRH stimuli (G-I). 
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Medical Sciences: Csernus and Schally tuting one of the exposures to LHRH with 100 mM potassium. One of our most potent LHRH antagonists, SB-75, even after a 9-min preincubation at a dose of 3 nM, did not affect significantly the LH response to potassium (Fig. 5 , response F).
DISCUSSION
In vitro characterization of the responses to LHRH antagonistic analogues greatly facilitates the evaluation of the bioactivity of the newly synthesized compounds. The dispersed cell pituitary superfusion system proved to be suitable to analyze not only the relative potency of the antagonists but also the dynamics of the action of the analogues on pituitary LH cells.
Based on the data obtained, we can draw the following conclusions.
(i) The pituitary cells in our superfusion system respond to pulsatile and continuous LHRH stimulation in a predictable, reliable way. Slight changes in the responsiveness, which were consistent throughout several experiments, might be a consequence of the combined effects of(a) the increase in LH synthesis, (b) depletion of the intracellular LH reserves, and (c) changes in the state of the release mechanism.
(ii) Continuous stimulation with 1 nM LHRH for 150 min does not induce significant desensitization in our system. The responsiveness under this condition changes in a manner similar to that following pulsatile stimulus with 3 nM LHRH. Several authors claimed that LH responsiveness decreased much more rapidly following continuous LHRH stimulation than after pulsatile stimulation (17) (18) (19) (20) . Analyses of the data presented in these papers reveal that in those experiments, the integral dose of LHRH used for stimulation and the total amounts of the released LH were much higher during continuous stimulation than during the control, pulsatile stimulation. Consequently, a significantly faster decrease of the intracellular LH reserves and/or faster exhaustion of the specific release mechanisms occurred, rendering impossible any comparison of the results of the two experimental groups. In our experiments, the average rates of LH release from the cells were similar following 1 (22) (23) (24) (25) (26) . Such changes may not occur in isolated membrane preparations widely used for receptor studies, which could result in significant differences between the results of in vivo experiments and data collected by tests on isolated membranes (22) (23) (24) (25) (26) . Since our aim is to elucidate the events that occur in living organisms, we consider the dynamic systems utilizing surviving cells to be promising for testing receptors. Superfusion methods might enhance our understanding of in vivo receptor interactions.
